David Scott

Researcher

BC Cancer Research Institute

Related Research

Related News & Events

Research Highlight|June 22, 2023

Study reveals cause for different outcomes for patients that experience early and late relapse of diffuse large B-cell lymphoma

A recent study sheds light on the cause behind the different outcomes of patients with diffuse large B cell lymphoma (DLBCL) who experienced a relapse...

Research Highlight|October 21, 2021

Lymphoma team publishes two papers on diffuse large B-cell lymphoma in major journal

Both papers help to better understand diffuse large B-cell lymphoma (DLBCL), a heterogeneous form of non-Hodgkin lymphoma that has an average five-yea...

Research Highlight|August 05, 2020

Researchers identify mutation associated with improved survival in Diffuse Large B-cell Lymphoma

BC-based researchers have found that TMEM30A loss affects the cell membrane, allowing drugs to be delivered into cancer cells more effectively and imp...

Research Highlight|June 03, 2019

EZH2 inhibitors could make immunotherapies more effective for a subset of patients with diffuse large B-cell lymphoma

A study by a group of BC-based scientists partly funded by the TFRI has discovered mutations responsible for changes in expression of major histocompa...

Research Highlight|December 03, 2018

Identification of new lymphoma sub-group by Terry Fox Research Institute-funded cancer researchers opens door for potential new treatments for hard-to-treat cancer

The discovery by BC researchers of a group of bad actors ‘hidden’ within a cohort of good ones may translate into new hope for cancer patients diagnos...

Research Highlight|September 06, 2017

Subtype-specific alterations in BCL2 linked to poor post-treatment outcomes in non-Hodgkin lymphoma

Subtype-specific alterations in a driver gene for non-Hodgkin lymphoma (BCL2) is strongly associated with poor patient outcomes after treatment.

All News & Events